New Research Suggests Bacteria May Help Combat Alzheimer’s Disease

Every three seconds, someone globally develops dementia, with Alzheimer’s disease being the most prevalent form, making up 60% to 70% of all cases. Despite advancements in understanding this condition, a cure remains elusive, partly due to the various, still not fully understood, causes behind Alzheimer’s.

Two key proteins, amyloid-beta and tau, are often highlighted in discussions about Alzheimer’s. Amyloid-beta creates sticky plaques on the surface of brain cells, hampering neuron communication, while tau forms tangled structures inside cells, ultimately leading to cell death. These plaques and tangles are characteristic features of the disease.

This understanding has spurred decades of research based on the amyloid hypothesis, leading to treatments designed to eliminate amyloid from the brain. Recently approved monoclonal antibody drugs target amyloid-beta but only show efficacy in early-stage disease, unable to reverse existing damage, and potentially causing serious side effects. Moreover, they do not address tau.

In an unexpected revelation, researchers, including myself, have discovered that a protein from Helicobacter pylori, commonly associated with stomach ulcers, can inhibit the toxic accumulation of both amyloid-beta and tau. This finding could represent a new approach in combating Alzheimer’s.

Initially, we were investigating H. pylori interactions with other microbes and how some bacteria form protective communities called biofilms using amyloid structures. This led us to wonder if H. pylori could influence amyloid assemblies in humans.

We focused on a protein known as CagA, which has two distinct halves: one known to trigger harmful effects in human cells, and the other, the N-terminal region, potentially offering protection.

Surprisingly, this N-terminal fragment, named CagAN, significantly reduced the formation of both bacterial amyloids and biofilms in other bacteria. Encouraged by these results, we tested CagAN’s effects on human amyloid-beta. In laboratory conditions, we found that treated samples showed a noticeable decrease in amyloid aggregation, even at low concentrations.

Using nuclear magnetic resonance and computer models, we explored how CagAN interacts with amyloid-beta. Remarkably, it also inhibited tau aggregation, indicating that it could influence multiple proteins related to Alzheimer’s.

Implications for Alzheimer’s Treatment

This research indicates that a protein fragment from H. pylori might effectively prevent the buildup of Alzheimer’s-related proteins, suggesting that bacterial proteins or drug derivatives could one day help stop initial Alzheimer’s signs.

Interestingly, we also found that this fragment blocked the aggregation of other proteins related to conditions like type 2 diabetes and Parkinson’s disease, showing its broader therapeutic potential. Even though these diseases affect different bodily parts, they might share similar mechanisms involving amyloid proteins, which CagAN could disrupt.

Nevertheless, it’s crucial to note that this research is still in its infancy, with experiments conducted purely in lab settings. However, the initial findings point toward new avenues for exploration.

We identified how CagAN prevents amyloid-beta and tau from forming clumps. It stops both protein groups from aggregating into harmful structures. Moving forward, we plan to delve deeper into these mechanisms and assess their effects in animal models.

This research raises an intriguing question about H. pylori. Historically seen only as a harmful bacterium, could it possess a protective side? Some studies have hinted at a connection between H. pylori infection and Alzheimer’s, though the relationship isn’t entirely clear.

Our findings introduce a new dimension to this conversation, suggesting that aspects of H. pylori may actually interfere with the processes leading to Alzheimer’s. As we advance our understanding, a more tailored approach may be required. Instead of trying to eliminate H. pylori entirely, it might be more beneficial to distinguish between its harmful and potentially beneficial components.

As the field of medicine shifts toward more personalized approaches, we might focus on how some microbes can work with human biology instead of against it.